Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
The advent of anti-TNF biological agents has been a massive advance in our treatment of RA and other inflammatory diseases. However, it is acknowledged that there are major drawbacks, the greatest being cost. There is, therefore, clearly a massive market for small molecular weight inhibitors that wo...
Main Authors: | Foxwell, B, Andreakos, E, Brennan, F, Feldmann, M, Smith, C, Conron, M |
---|---|
格式: | Journal article |
语言: | English |
出版: |
2003
|
相似书籍
-
Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717.
由: Sumariwalla, P, et al.
出版: (2009) -
Cytokines and anti-cytokine biologicals in autoimmunity: present and future.
由: Andreakos, E, et al.
出版: (2002) -
Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.
由: Foxwell, B, et al.
出版: (2000) -
Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist.
由: Neve, R, et al.
出版: (1996) -
Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
由: Brennan, F, et al.
出版: (1995)